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Abstract
Background: Previous studies have suggested that melatonin may produce antinociception through peripheral and central
mechanisms. Based on the preliminary encouraging results of studies of the effects of melatonin on pain modulation, the
important question has been raised of whether there is a dose relationship in humans of melatonin on pain modulation.
Objective: The objective was to evaluate the analgesic dose response of the effects of melatonin on pressure and heat pain
threshold and tolerance and the sedative effects.
Methods: Sixty-one healthy subjects aged 19 to 47 y were randomized into one of four groups: placebo, 0.05 mg/kg
sublingual melatonin, 0.15 mg/kg sublingual melatonin or 0.25 mg/kg sublingual melatonin. We determine the pressure
pain threshold (PPT) and the pressure pain tolerance (PPTo). Quantitative sensory testing (QST) was used to measure the
heat pain threshold (HPT) and the heat pain tolerance (HPTo). Sedation was assessed with a visual analogue scale and
bispectral analysis.
Results: Serum plasma melatonin levels were directly proportional to the melatonin doses given to each subject. We
observed a significant effect associated with dose group. Post hoc analysis indicated significant differences between the
placebo vs. the intermediate (0.15 mg/kg) and the highest (0.25 mg/kg) melatonin doses for all pain threshold and sedation
level tests. A linear regression model indicated a significant association between the serum melatonin concentrations and
changes in pain threshold and pain tolerance (R
2=0.492 for HPT, R
2=0.538 for PPT, R
2=0.558 for HPTo and R
2=0.584 for
PPTo).
Conclusions: The present data indicate that sublingual melatonin exerts well-defined dose-dependent antinociceptive
activity. There is a correlation between the plasma melatonin drug concentration and acute changes in the pain threshold.
These results provide additional support for the investigation of melatonin as an analgesic agent.
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Melatonin is the major hormone synthesized by the pineal gland
and is mainly involved in the control of circadian rhythm [1].
However, melatonin is also involved in the regulation of other
systems such as the pain system. In fact, the antinociceptive effect
of melatonin has been demonstrated in animal models of acute
pain [2,3], inflammatory pain [4] and neuropathic pain [5]
Preliminary studies in humans have shown melatonin effects on
some pain syndromes, especially fibromyalgia [6] and acute
postoperative pain [7,8,9]. Despite these initial positive results, the
dose-response effect of melatonin on pain has not been explored.
Melatonin interacts with two receptors (MT1 and MT2) at
different sites in the brain [10]. However, its antinociceptive effects
are not fully understood. Previous studies have suggested that this
hormone could have an effect on the spinal cord and thus alter
nociceptive transmission at this level [11]. Melatonin also has
modulatory functions on opioid and gamma-aminobutyric acid
(GABA) systems [12,13,14]. Furthermore, melatonin may have a
peripheral effect as shown by inhibitory activity on the release of
pro-inflammatory cytokines at peripheral sites [15]. Therefore,
melatonin may mediate antinociception through peripheral and
central mechanisms. Based on the preliminary encouraging results
of studies of the effects of melatonin on pain modulation, the
important question of whether there is a dose relationship in
humans of melatonin on pain modulation has been raised. To fill
this gap in knowledge, we decided to test the hypothesis that
melatonin would have a dose-response antinociceptive effect. To
measure pain in this study, we chose to measure pain threshold
and tolerance. Although the pain threshold is fairly constant, the
pain tolerance level, which is defined as the amount of pain a
subject is prepared to put up with, varies enormously. Interest-
ingly, patients do not usually seek medical advice until they are
beyond their pain tolerance. For a given noxious stimulus, the
intensity with which pain is felt varies from person to person, and a
distinction has to be made between an individual’s pain threshold
and pain tolerance [16]. This was defined in experimental pain
models in healthy human volunteers by measuring analgesic drug
effects using a noninvasive, non-noxious, standardized and
repeatedly applicable stimulus[17].
Thus, we investigated the melatonin dose-response effect on
pain threshold after considering the inter-individual and intra-
individual variability. We tested the pressure pain tolerance, the
heat pain tolerance and the sedative effect. The effect of melatonin
on pain measurement was adjusted by the sedation level.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Subject and study design
After obtaining approval from the Research Ethics Committee
of the Hospital de Clı ´nicas de Porto Alegre, 61 white healthy
volunteers with a mean age of 26.8 y (the range was 19–47 y) were
enrolled into the randomized, parallel, double-blind, placebo-
controlled study. The study was conducted in accordance with the
Declaration of Helsinki on biomedical research involving human
subjects, and written informed consent was obtained from the
participants.
The volunteers were recruited from the general population by
postings in universities, on the Internet and in public places in the
Porto Alegre area. Subjects were considered eligible to participate
if they were aged between 19 and 49 y. Interested individuals were
screened for eligibility by phone. They answered a structured
questionnaire assessing the following variables: current acute or
chronic pain conditions, use of analgesics in the past week,
rheumatologic disease, clinically significant or unstable medical or
psychiatric disorder, history of alcohol or substance abuse in the
past 6 months, neuropsychiatric comorbidity, and use of central
nervous system-affecting medications. Patients responding affir-
matively to questions about any of these conditions were excluded
from the study. In Brazil, economic incentives for research
participation are not allowed.
Sample size justification
The number of subjects in each study group was determined
based on our previous study [18]. An a priori estimate indicated
that a total sample size of 60 divided in four balanced treatment
groups (n=15) was required to detect an increase of 1.31 kg/cm
2/
second in pain pressure threshold [mean standard deviation (SD)
0.9 kg/cm
2/second] in the melatonin group and a difference of
2.5 [mean SD 3uC (Celsius)] in heat pain threshold, with a power
of 0.8 and an a level of 0.05. The sample size estimated a priory
was defined by pain threshold (pressure and heat) considering that
across healthy individuals it is expected a higher variability in pain
threshold compared with the pain tolerance [19]. However, the
power of analysis for the pain threshold (heat and pressure), as well
as for pain tolerance (pressure and heat) it was higher than 80%
with a 2-tailed with an a-error of 0.01.
Study plan
The data were collected at the Clinical Research Center of the
Hospital de Clı ´nicas de Porto Alegre. The volunteers were asked
to abstain from alcohol and excessive coffee consumption (defined
as at least 5 cups of coffee day, a dose that corresponds to 400 mg
of caffeine) for 24 h before testing and from drinking and eating
for 6 h before testing. Study sessions were performed in a quiet,
non-stressful environment at the same air-conditioned location,
and the sessions always started at the same time in the afternoon.
The volunteers rested comfortably in a semi-recumbent position
during the experiments and were monitored with non-invasive
blood pressure, pulse oximetry and a BIS (bispectral index) Quatro
Sensor (Aspect Medical Systems model A-2000; Aspect Medical
Systems, Newton, MA), which was applied on the forehead and
connected to the BIS monitor. After a trial run to familiarize the
volunteers with the procedures, two test series were performed: at
baseline and 30 minutes after the intervention. The subjects were
always assessed by the same researcher (L. Stefani), an anesthe-
siologist with extensive experience in clinical and experimental
pain assessment, who systematically read the instructions and
explained the standardized experimental procedure using a
modified previously published protocol [19] for quantitative
sensory testing (QST) assessment. They received instructions to
pushing the rescue button only when they actually get painful.
After the test series, a venous blood sample was taken for analysis
of the plasma melatonin concentration. The blood samples were
immediately stored at 4uC and centrifuged at 3500 rpm for
10 min after the last test series. The plasma was frozen at 280uC
for later analysis.
Interventions
The intervention involved one of three doses of sublingual
melatonin (Sigma Chemical, Germany, batch-by-batch certificates
of analysis for authenticating the purity of each batch provided):
0.05 mg/kg, 0.15 mg/kg, 0.25 mg/kg (maximum dose 20 mg), or
placebo. The preparation of the melatonin solution was performed
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The dose-adjustment was performed by changing the concentra-
tion of melatonin in the vehicle. This solution was combined with
0.5 ml of 10% glucose solution. The placebo was an equivalent
volume of 10% glucose solution. The nurse prepared the study
drugs using the melatonin solution (20 mg/ml) in needleless
syringes marked only with coded labels to maintain the double-
blinded nature of the study. Patients received oral and written
instructions that they could not swallow the liquid nor talk while
the liquid was in their mouth.
Randomization and blinding
We used a fixed block size of 12 to ensure that equal numbers of
participants were randomized into the four groups. A computer
random number generator stratified by gender assign the patients
to one of three melatonin doses or the placebo. Before the
recruitment phase, opaque envelopes containing the allocated
treatment were sealed and numbered sequentially. The envelopes
were only allowed to be opened after the subject signed the
consent form; the nurse who administered the medications opened
the envelopes – this nurse was not involved in other components of
Figure 1. Flow and number of patients in each phase of the study.
doi:10.1371/journal.pone.0074107.g001
Table 1. Demographic data and psychological profiles (n=61).
Variable Placebo Melatonin Melatonin Melatonin FP
0.05 mg/kg 0.15 mg/kg 0.25 mg/kg
(n=15) (n=15) (n=15) (n=16)
Male/Female J 7/8 7/8 7/8 8/8 __
Age (years) { 25.13 (5.50) 25.2 (5.07) 25 (6.44) 23.68 (2.72) 4.7 0.72
Body index (kg/m
2) { 22.50 (4.03) 24.16 (6.47) 22.76 (3.29) 22.75 (2.71) 0.92 0.43
Beck Depressive Inventory
symptoms { 3.2 (2.54) 4.8 (5.7) 4.0 (2.73) 3.37 (2.87) 0.57 0.63
Trait Anxiety { 21.13 (3.77) 22.26 (5.6) 19.85 (3.15) 18.54 (4.59) 0.09 0.96
State Anxiety { 19.0 (3.0) 18.93 (5.4) 19.21(2.63) 20.25 (4.2) 0.92 0.98
{Compared by ANOVA; J compared using Chi-Square.
doi:10.1371/journal.pone.0074107.t001
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BIS index HPT(6C) HPT (6C) PPT PPTo
(Kg/cm
2/second) (Kg/cm
2/second)
VAS sedation score 20.32 0.18 0.20 0.14 0.27
(P=0.03)* (P=0.17) (P=0.15) (P=0.45) (P=0.15)
BIS index – 20.07 20.10 20.21 20.24
(P=0.60) (P=0.42) (P=0.08) (P=0.05)
*Spearman correlation coefficient (rs) is significant at the 0.05 level (2-tailed).
Mean of the BIS at 30 min after medication (BIS index); mean Delta sedation score on the VAS (VAS sedation score); heat pain threshold (HPT); score on heat pain
tolerance (HPTo); pain pressure threshold (PPT); mean Delta pressure pain tolerance (PPTo).
doi:10.1371/journal.pone.0074107.t002
Table 3. The mean delta score (SD) (post-treatment values minus pre-treatment values) of the pressure and heat pain threshold,
the pressure pain tolerance (PPTo) and the heat pain tolerance (HPTo) tests or sedation score (n=61).
Treatment Mean (SD) Mean (SD) Median P SDM
(Delta) (Quartile 75;25)
Pain pressure threshold(kg/cm2/second){
Placebo (n=15) 6.71 (1.57) vs. 6.64 (1.50) 0.08 (0.03)
a 0.40 (0.23; 0.90) 0.001 0.05
Melatonin 0.05 mg/kg (n=15) 6.79 (1.54) vs. 6.59 (1.54) 0.20 (0.35)
a 0.98 (0.27; 1.60) 0.13
Melatonin 0.15 mg/kg (n=15) 6.48 (1.89) vs. 5.54 (1.58) 0.94 (0.79)
b 1.06 (0.65; 1.43) 0.50
Melatonin 0.25 mg/kg (n=16) 7.37 (1.74) vs. 6.02 (1.64) 1.35 (1.26)
b 1.06 (0.66; 1.43) 0.78
Heat pain threshold (6C){
Placebo (n=15) 43.23 (2.51) vs.42.90 (2.43) 0.33 (2.11)
a 0.67 (0.37; 1.10) 0.001 0.13
Melatonin 0.05 mg/kg (n=15) 43.10 (2.42) vs. 42.56 (2.37) 0.54 (0.96)
a 2.20 (1.41; 2.96) 0.37
Melatonin 0.15 mg/kg (n=15) 44.71 (2.91) vs. 42.75 (3.15) 1.96 (1.08)
b 2.38 (1.72; 3.65) 0.67
Melatonin 0.25 mg/kg (n=16) 45.05 (3.05) vs. 42.56 (3.56) 2.49 (2.88)
b 2.38 (1.72; 3.65) 0.82
Score on heat pain tolerance (HPTo) (6C){
Placebo (n=15) 43.23(2.16) vs. 42.50 (2.49) 0.32 (0. 8)
a 0.87 (0.73; 1.08) 0.001 0.15
Melatonin 0.05 mg/kg (n=15) 43.10(2.22) vs. 42.28 (2.32) 0.82 (0. 84)
a 1.36 (1.03; 1.56) 0.40
Melatonin 0.15 mg/kg (n=15) 44.91 (2.71) vs.42.68 (3.15) 2.23 (0.49)
a, b 1.87 (1.53; 2.43) 0.83
Melatonin 0.25 mg/kg (n=16) 45.05 (3.05) vs.41.74 (3.56) 3.31 (0.73)
b 1.98 (1.70; 2.31) 1.09
Mean delta pressure pain tolerance (kg/cm2/second){
Placebo (n=15) 6.89(1.87) vs. 6.08 (1.50) 0.81 (0.57)
a 0.90 (0.63; 1.17) 0.001 0.43
Melatonin 0.05 mg/kg (n=15) 7.38 (1.74) vs. 6.59 (1.54) 0.79 (0.74)
a, b 1.24 (0.90; 1.58) 0.45
Melatonin 0.15 mg/kg (n=15) 8.29 (1.98) vs. 6.89 (1.58) 1.40 (0.82)
a, b 1.61 (1.50; 2.18) 0.70
Melatonin 0.25 mg/kg (n=16) 8.43 (1.74) vs. 6.98 (1.64) 1.45 (0.78)
b 2.04 (1.76; 2.19) 0.83
Mean delta sedation score on the VAS{
Placebo (n=15) 2.19 (1.41) vs.1.21 (0.97) 0.98 (1.76)
a .19 (0.07; 2.47) 0.16 0.70
Melatonin 0.05 mg/kg (n=15) 3.48 (1.87) vs.1.65 (1.82) 1.83 (1.14)
a 1.57 (0.53; 2.54) 0.98
Melatonin 0.15 mg/kg (n=15) 3.82 (1.94) vs. 1.45 (1.62) 2.37 (1.70)
a 2.53 (1.28; 3.48) 1.22
Melatonin 0.25 mg/kg (n=16) 4.47 (1.51) vs. 1.78 (1.52) 2.69 (1.50)
b 2.53 (1.65; 4.28) 1.78
Mean of the BIS during 60 min after medication $
Placebo (n=15) 97.42 (1.84) vs. 97.63 (2.0) 20.21 (1.70)
a 7.28 0.0001 0.11
Melatonin 0.05 mg/kg (n=15) 97.21 (1.93) vs. 97.92 (2.43) 20.71 (2.07)
b 0.37
Melatonin 0.15 mg/kg (n=15) 96.17 (1.82) vs. 97.42 (2.21) 2.1.25 (1.82)
c 0.69
Melatonin 0.25 mg/kg (n=16) 94.75 (2.94) vs. 97.14 (1.70) 22.39 (1.70)
c 0.82
Visual analogue scale (VAS).
Different superscripts (a, b, and c) indicate significant differences among treatment groups according to the Bonferroni test.
{Kruskal-Wallis test with Dunn’s Multiple Comparison Test to identify changes between groups.
$ Mixed ANOVA model.
Standardized mean difference (SMD) [(pre minus post)/baseline standard deviation]. The size effect was interpreted as follows: small, 0.20;, moderate, 0.50–0.60 and
large, 0.80.
doi:10.1371/journal.pone.0074107.t003
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evaluators did not participate in enrollment decisions. Two
investigators who were not involved in subject evaluation
performed randomization. Other individuals who were involved
in patient care were unaware of the treatment group to which the
patients belonged.
Outcomes
The main primary outcome was the heat pain threshold and the
pressure pain threshold. Pain tolerance was considered as the main
secondary outcome and the sedation level as another secondary
outcome. The pain threshold, pain tolerance and sedation level as
reported using a VAS were measured at baseline and 30 min after
administration of the medication. The sedation level was also
measured continuously using the BIS for 30 min.
Experimental pain tests
Heat pain thresholds and tolerance. Quantitative sensory
testing (QST) was used to assess heat pain thresholds using the
method of limits with a computer Peltier-based device thermode
(30630 mm) [21]. The thermode was attached to the skin on the
ventral aspect of the mid-forearm. The baseline temperature was
set at 32uC and was increased at a rate of 1uC/s to a maximum of
52uC. This slow rise time was selected as a test of pain, which is
primarily evoked by stimulation of C-nociceptive afferents as
previously demonstrated [22]. Each participant was asked to press
a button as quickly as possible at the moment the stimulation
became painful. Three assessments were taken with an interstim-
ulus interval of 40 s [23], and the thresholds were calculated by
taking the average temperature of the three assessments. The
position of the thermode was slightly altered between trials
(although it remained on the left ventral forearm) to avoid either
sensitization or the response suppression of cutaneous heat
nociceptors. The same equipment was used to determine the
maximally tolerated temperature on the ventral aspect of the mid
forearm. Starting at a baseline temperature of 32uC, the thermode
was heated at a rate of 1.0uC/s. The volunteer pressed a button
when he/she did not want the temperature to be increased any
further (pain tolerance is the maximal temperature that a person is
able to tolerate; the cutoff limit was 52uC), which caused the
thermode to cool to the baseline temperature. When the heat was
raised up to a maximum of 52uC and the subject did not feel pain
at that temperature, the real pain threshold was considered
unknown.
Pressure pain test. A Fisher’s pressure algometer (Pain
Diagnostics and Thermography, Great Neck, NY 11023) [24] was
used to determine pain pressure detection and pain pressure
tolerance. The pressure was gradually increased at a rate of 1 kg/
cm
2/second. A probe with a surface area of 1 cm
2 was applied
perpendicular to the tibial surface. Prior to the test trial, the
volunteer learned to differentiate the perception of pressure from
the perception of the onset of pain. The subject was then
instructed to verbally report the perception of pain onset. Subjects
were asked to say ‘stop’ immediately after a discernible sensation
of pain (distinct from pressure or discomfort) was felt. At this point,
the experimenter immediately retracted the algometer [24]. The
average value of three successive readings taken at intervals of 3–
5 min was recorded as the pain pressure threshold [24]. We also
measured the pain pressure tolerance, which was defined as the
maximally tolerated pressure applied to the tibial surface. Subjects
were asked to say ‘stop’ when they did not want the pressure to be
increased any further (pain pressure tolerance is the maximum
level of pressure that a person is able to tolerate; the cutoff limit
was 10 kg/cm
2).
The clinical assessment of sedation was determined by
simultaneous recording using a visual analogue scale (VAS)
ranging from zero (awake) and 100 mm (complete sleepiness).
The BIS was obtained with BIS (model A-2000; Aspect Medical
Systems, Newton, MA). After electrode placement above the
bridge of the nose, over the temple area, and between the corner
Figure 2. Dose-concentration curve comparing the mean concentration achieved at 30 min following sublingual doses of 0.05, 0.15
or .25 mg/kg (n=61). Serum plasma melatonin level at 30 min after sublingual administration. Error bars indicate the standard error of the mean.
Asterisks above the bars indicate the significant difference (P,0.05) at the time points. (*) Differences between placebo and melatonin. (**)
Differences between 0.05, 0.15, and 0.25 mg/kg doses. All comparisons were made using a regression analysis model, followed by Bonferroni test for
post-hoc multiple comparisons. F(3:57)=127; (P,0.0001); R
2=0.86.
doi:10.1371/journal.pone.0074107.g002
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impedance testing to ensure acceptable signal reception. The
electrodes were repositioned or replaced if impedances increased
enough to impair the EEG evaluation. A reading of zero indicated
no brain activity, and a reading of 100 indicated a fully awake
state. The BIS score correlates quantitatively with the alertness of
sedated patients without being confounded by evaluator or patient
bias [25]. Data from the BIS monitor were recorded for the study
group for 30 min after melatonin administration.
Assessment of demographic characteristics, depressive
symptoms and anxiety
All of the tests used in the present study were validated for the
Brazilian population and performed in the presence of a previously
trained evaluator.
a) Demographic data were assessed using a standardized
questionnaire.
b) Depressive symptoms were assessed by the Beck Depression
Inventory (BDI). The final scores ranged from 0 to 63 [26].
Figure 3. Effect of serum plasma melatonin of all of the volunteers on pressure pain threshold (A) and heat pain threshold (B)
(n=61).
doi:10.1371/journal.pone.0074107.g003
Dose-Response Effect of Melatonin on Pain
PLOS ONE | www.plosone.org 6 October 2013 | Volume 8 | Issue 10 | e74107c) Anxiety was measured with the refined version of the Rasch
analysis of the State-Trait Anxiety Inventory (STAI), which
was adapted to Brazilian Portuguese [27]. State anxiety (a
situation-driven transient anxiety) and trait anxiety (stable
personality disposition reflecting general level of fearfulness)
were evaluated. Each state item was given a weighted score of
1 to 4. The total number of items was 13, and the possible
scores range was 13 to 52. Each trait item was given a
weighted score of 1 to 3. The total number of items was 12,
and total possible score ranged was from 12 to 36. Higher
scores denoted higher levels of anxiety.
Melatonin determination
The blood samples were centrifuged in plastic tubes for 10 min
at 35006 ga t4 uC, and the serum was stored at 280uC for the
hormone assays. To assess bioavailability, serum melatonin was
determined by ELISA using commercial kits from MP Biomedical
Inc. (Irvine, California, USA) that employed the basic principles of
competitive immunoassays [28]. The detection limit of the ELISA
assay was 0.3 ng/mL (300 pg/ml).
Statistical analyses
The differences between the groups on baseline were examined
by analysis of variance (ANOVA) for parametric variables, and
categorical variables were examined by chi-square or Fisher’s
exact tests given that our main independent outcome (intervention)
was also categorical. Linear regression and slope analysis were
performed to obtain the serum melatonin concentration and pain
threshold relationship. A Spearman correlation coefficient (rs) was
used to assess the correlation between VAS and BIS sedation
scores with pain threshold and pain tolerance.
The results were evaluated using the absolute mean variation on
heat pain thresholds and pressure pain threshold, heat and pain
pressure tolerance and on scores of delta values (post-treatment
minus pre-treatment). Given the several outcomes of pain
threshold levels did not present normal distribution we analyzed
data using Kruskal-Wallis test with Dunn’s Multiple Comparison
Figure 4. Effect of serum plasma melatonin of all of the volunteers on pressure pain tolerance (A) and heat pain tolerance (B)
(n=61).
doi:10.1371/journal.pone.0074107.g004
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(obtained each minute during a 30-min period), we conducted a
group analysis with a mixed ANOVA model in which the
independent variables were time, treatment (placebo vs. melatonin
0.05, 0.15 and 0.25 mg), the interaction term time vs. the
treatment group and subject ID. We performed post hoc analysis
using paired t tests to assess the effects of each treatment group. To
ensure normally distributed data, we performed a log transfor-
mation for pain threshold (heat and pressure), pain tolerance (heat
and pressure), as well the serum plasma melatonin level to assess
the relationship between serum plasma melatonin levels and
analgesic effects. Within-group the standardized mean difference
(SMD) was computed in terms of the ratio between the mean
change and the baseline standard deviation. The SMD was
interpreted as follows: small, 0.20; moderate, 0.50–0.60 and large,
0.80[29]. All of the analyses were performed in assuming
intention-to-treat, hence including all of the randomized subjects
for whom there were observations in the study outcomes.
Formal testing of observed and unobserved bias (on the
assumption that blinding may not have been completely effective)
using the Berger-Exner test [30] were also performed. The
analyses were performed with GraphPad Prism version 4.00 for
Windows (GraphPad Software, USA) and SPSS version 18.0
(SPSS, Chicago, IL).
Results
Sixty-one subjects were randomized into one of four groups
(Figure 1). The subject characteristics are summarized in
Table 1. The demographic characteristics are shown for each
group of subjects assigned to receive one of three doses of
melatonin or placebo. The ages of the subjects and the gender
distribution did not differ between the four groups. The Berger-
Exner tests supports the lack of evidence for observed and
unobserved bias in treatment group assignment. Controlling for
treatment arm, the P-values for the partial correlation between
heat pain threshold and pain pressure threshold (the main
outcomes) and the dose-group in the block at the time of random
assignment to therapy was .0.4 in each of the four groups.
Between-group changes in pain threshold and sedation
This study no find significant correlation between the pain
threshold and pain tolerance with sedation score and the BIS
value, as presented in Table 2.
The results of the effects of melatonin on pain threshold, pain
tolerance, sedation scores as well in BIS are shown in Table 3.
The post hoc analysis indicated significant differences between the
placebo and the intermediate and highest melatonin doses in all of
the tests.
Dose-concentration curve for the pain threshold
The dose-concentration response curve for melatonin was
subproportional to the dose given to each patient. Variations in
sublingual melatonin doses accounted for 97% of the variance in
plasma melatonin concentrations (Figure 2). This figure presents
the dose-concentration curve generated from three different doses
of melatonin, which can be used to determine potency and
maximal efficacy.
Comparisons of the concentration indicate a linear relationship
between serum plasma melatonin levels and analgesic effects
(Figures 3A,B; 4 A,B). The correlations between the serum
melatonin concentrations and the change in the outcome variables
(pain threshold and pain tolerance) are derived from the linear
regression model. The melatonin serum concentration accounted
for 53.8% and 49.2% of the variance of pain pressure threshold
and heat pain threshold, respectively (Figures 3 A, B).
The melatonin serum concentration accounted for 58.4% and
55.8% of the variance of pain pressure tolerance and heat pain
tolerance, respectively (Figures 4 A, B). Eight of the subjects
(13.3%) did not feel pain even after heating up to the maximum of
52uC, hence their real pain threshold remained unknown.
Discussion
The present study presented dose-concentration curves for the
effects of melatonin on heat and pressure pain tests. Serum
melatonin concentrations are within the normal dynamic range for
dose melatonin concentrations (Figure 2) with rapid elevation,
which indicates that the rate and extent of absorption of melatonin
(bioavailability) is linear with the dose after sublingual adminis-
tration. Interestingly, sublingual melatonin induced a dose-
dependent analgesic effect on pain threshold and pain tolerance.
A single dose of at least 0.15 mg/kg produced a significant
increase in both pain measurements (threshold and tolerance) for
heat and pressure (Table 3). Higher doses produced size effect
increases in both pain threshold and pain tolerance (Table 3).
The subjects in the present study did not experience any side
effects besides sedation, which suggests that the different doses that
were used were adequate but not excessive. The subjects who
received 0.15 mg/kg or 0.25 mg/kg of sublingual melatonin
presented a statistically significant increase in sedation (based on
the BIS data) compared with those who received placebo or the
lowest melatonin dose (Table 3).
The data obtained in the present study are best described with a
dose-concentration curve. Our findings distinguish between inter-
individual and intra-individual variability of the drug effect, which
may be important for the interpretation of the results. The
comparisons of mean delta also allowed for determinations of the
dose-response effect for each individual. This effect was revealed
and maintained independently of the type of stimulus applied
(pressure or thermal). The consistency of the findings of the
present study supports the hypothesis of a melatonin dose-response
effect. The experiment was conducted in a controlled setting,
which excludes the influence of several confounding factors
observed in clinical pain, such as baseline pain, psychological
factors and the presence of other analgesics.
The present findings corroborate positive results reported for
melatonin in previous clinical studies assessing acute pain and
chronic pain [6,8,9], as well in animal models [31] of nociceptive
pain, such as the tail-flick [32], hot-plate [14,33], tail electric
stimulation and hind paw pinch [34] tests. Although a dose-
dependent antinociceptive effect has been shown in some previous
preclinical studies [13,32], even with small melatonin doses, we
cannot perform direct comparisons of dose-response curves
between animal and human models because several aspects
related to the varying doses (20 to 200 mg/kg), route of
administration (intraperitoneal or intracerebroventricular) and
kinetic parameters are species specific.
In the present study, the effect on nociceptive pain may be
observed through changes in the thermal and pressure pain
threshold, as well in pain tolerance. When comparing the effect on
SMD presented in Table 3, it is possible to see that a dose of
0.15 mg/kg increased PPTo 28.57% (0.5 vs. 0.7) compared to the
PPT test effect. This increase was 19.28% (0.67 vs. 0.83) for HPTo
compared to the effect on HPT, respectively. Although such
increment was relatively small, it was equivalent to the analgesic
effect observed in other trials comparing active treatment with
placebo [35].
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sized in a number of extrapineal sites, including the spinal cord,
which indicates that this hormone could act as a paracrine signal
in addition to its endocrine action [36]. Furthermore, melatonin
receptors are abundant in the spinal cord [37]. Thus, melatonin
could play a role in the modulation of nociceptive transmission at
this level [11]. Melatonin also modulates opioid and gamma-
aminobutyric acid (GABA) systems [12,13,14], but it is not
possible to dissociate the effect of each individual neurobiological
system in human experimental and clinical studies. Indeed, only
the net effect can be assessed. Studies have also suggested that
additional pathways play a role in the analgesic actions of
melatonin, such as nuclear signaling pathways, receptor-indepen-
dent radical scavenging, and inhibition of the release of
proinflammatory cytokines at peripheral sites. In addition, the
highly lipid-soluble nature of melatonin allows it to easily penetrate
the blood-brain barrier. Therefore, melatonin may cause anti-
nociception through both peripheral and central mechanisms, and
the effect may be related to dose, as shown in present study
(Table 3). In the present study, the BIS value decreased with
increasing melatonin dose. Although there were significant
differences among the sedation levels of the individual groups,
we do not believe that the differences are clinically significant. The
magnitude of the differences is small because only a mild level of
sedation was observed, and all of the subjects were easy aroused by
verbal stimuli throughout the study. This hypothesis is supported
by our findings, as neither pain threshold nor pain tolerance scores
were altered by sedation level (Table 2). Accordingly, to obtain
non-invasive and objective information about the clinical sedative
effect, we used a BIS. The BIS permitted us to identify if a drug
induced sedation in a dose-dependent manner, without the
interference of evaluator bias[38]. However, further studies should
assess if the sedation level observed with these doses has an impact
on function in daily life because sedation is a major problem with
most currently available pain drugs (i.e., antidepressants, anticon-
vulsants, and opioids).
It is important to assess the strengths and limitations of the
clinical trial we conducted. We conducted this trial according to
the CONSORT guidelines and given that we used the Delphi List
(a criteria list for quality assessment of RCTs), our trial can be
considered to be of strong quality because all eight items in this
scale can be positively scored in our RCT [39]. However, some
methodological choices should be taken into account in the
interpretation of these findings. i) It is important to emphasize that
the methodology used does not allow the determination of the
duration of effect. ii) It is also important to consider that because
of inter-individual pharmacokinetics, we may have missed the
peak effect in some subjects. iii) The permuted blocks method of
randomization was used, although it has been described that such
method could allow for prediction of future allocations. Thus,
formal testing for selection bias (on the assumption that blinding
may not have been completely effective) using the Berger-Exner
test was performed. This test found no evidence of selection or
allocation bias. Also, several strategies were used to prevent
patients and evaluator team from unblinding, formal assessment
for awareness of the allocation (either active or placebo) was not
performed. However, all outcomes assessed using different
techniques (heat, pressure, sedation) were in the same direction
and in dose-response gradient, hence unblinding is unlikely to
have influenced the direction of our conclusions. iv) New studies
are needed to explore the pharmacokinetics parameters that could
explain the subproportional increase of plasma melatonin accord-
ing to exposure dose and the tendency to plateau. v) Although a
randomized clinical trial treating patients with endometriosis
during two months using 10 mg at bed time did not report side
effects that interfered with daily life activities [40], further
randomized clinical trials would be required to assess better
efficacy and possible side effects. Finally, although the dose-
response effect was observed in these healthy subjects, further
studies are required to test the dose-response effect of melatonin on
clinical pain with diverse physiopathological mechanisms before
any definitive conclusions can be drawn.
The present data indicate that sublingual melatonin exerts a
well-defined dose-dependent antinociceptive activity, and there is
a correlation between the plasma melatonin drug concentration
and the acute changes in pain threshold. These results provide
additional support for the investigation of melatonin as an
analgesic agent.
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